Trianz Releases Acceliant 6.1 after R&&D Partnership with REGISTRAT-MAPI


Company News Release

REGISTRAT-MAPI and Trianz Solutions are pleased to announce a further strengthening of their relationship via the release of Acceliant V6.1. REGISTRAT-MAPI has utilized Acceliant since 2007 for many of their Late Phase clinical studies. Acceliant V6.1, released earlier this year incorporates a number of new functional enhancements and UI architectures.

Acceliant 6.1 is a full life cycle e-Clinical Trials EDC platform comprised of Clinical Data Management, regulatory compliant Document Management, core Trial Management facilitating collaboration and site management, and business intelligence capabilities. Acceliant features a proprietary Accelerated Trial Builder, which allows non-technical users to accomplish end-to-end configuration and build of a trial without the need for any programming. The Accelerated Trial Builder enables users to define data-fields, edit checks, code lists, complete CRF layouts, validate the build and then deploy the trial with a single click.

Based on an integrated design and architecture, all Acceliant modules and features have been designed and built as a single native platform. Version 6.1 includes technology-driven usability features that are beneficial when working with large trials involving thousands of sites and patients; several design improvements for efficiently handling large scale data sets; powerful capabilities for import/export of large data sets; and rapid edit and validation of test data. These enhancements provide benefits for all trial phases.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.